Ticrynafen

CHEMBL267744 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

331.2 g/mol

LogP

4.1

Phase

4

Ticrynafen (tienilic acid) is a uricosuric diuretic and antihypertensive agent that inhibits renal tubular reabsorption of urate while also blocking sodium and chloride reabsorption. It was withdrawn from the market due to severe hepatotoxicity, including fatal hepatic necrosis associated with drug-metabolite-induced autoimmune liver injury. Its combined uricosuric and antihypertensive properties were clinically attractive, but the idiosyncratic hepatotoxic mechanism involving CYP2C9-generated reactive metabolites made it unsafe.

Moleküler Ağırlık

331,2000 g/mol

LogP

4,10

TPSA

91,80 Å²

Lipinski RO5

Geçer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl

InChI

InChI=1S/C13H8Cl2O4S/c14-11-7(13(18)9-2-1-5-20-9)3-4-8(12(11)15)19-6-10(16)17/h1-5H,6H2,(H,16,17)

Molecular Formula

C13H8Cl2O4S

HBD / HBA

1 / 5

Döndürülebilir Bağlar

5

Ağır Atomlar

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

Ticrynafen (tienilic acid) is a uricosuric diuretic and antihypertensive agent that inhibits renal tubular reabsorption of urate while also blocking sodium and chloride reabsorption. It was withdrawn from the market due to severe hepatotoxicity, including fatal hepatic necrosis associated with drug-metabolite-induced autoimmune liver injury. Its combined uricosuric and antihypertensive properties were clinically attractive, but the idiosyncratic hepatotoxic mechanism involving CYP2C9-generated reactive metabolites made it unsafe.

Yes, Ticrynafen is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL267744. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 38409. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Ticrynafen PillFYI'da

Yapı

Hızlı Veriler

Formül: C13H8Cl2O4S

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.